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Summary 24 
Cattle vaccination against bovine tuberculosis (bTB) has been proposed as a 25 
supplementary method to help control the incidences of this disease. Bacillus 26 
Calmette-Guérin (BCG) is currently the only viable candidate vaccine for immunisation 27 
of cattle against bTB, caused by Mycobacterium bovis (M. bovis).  28 
In an attempt to characterise the differences in the immune response following M. 29 
bovis infection between BCG vaccinated and non-vaccinated animals, a combination of 30 
gross pathology, histopathology and immunohistochemical (IHC) analyses was used. 31 
BCG vaccination was found to significantly reduce the number of gross and 32 
microscopic lesions present within the lungs and lymph nodes. Additionally, the 33 
microscopically visible bacterial load of stage III and IV granulomas was reduced. 34 
IHC using cell surfaces markers revealed the number of CD68+ (macrophages), CD3+ 35 
(T-lymphocytes) and WC1+ cells (γδ T-cells) to be significantly reduced in lymph node 36 
granulomas of BCG vaccinated animals, when compared to non-vaccinated animals. B 37 
lymphocytes (CD79a+) were significantly increased in BCG-vaccinated cattle for 38 
granulomas at stages II, III and IV. IHC staining for iNOS showed a higher expression in 39 
granulomas from BCG vaccinated animals compared to non-vaccinated animals for all 40 
stages, being statistically significant in stages I and IV. TGFβ expression decreased 41 
alongside the granuloma development in non-vaccinated animals, whereas BCG 42 
vaccinated animals showed a slight increase alongside lesion progression. IHC analysis 43 
of the cytokines IFN-γ and TNFα demonstrated significantly increased expression 44 
within the lymph node granulomas of BCG vaccinated cattle. This is suggestive of a 45 
protective role for IFNγ and TNFα in the response to M. bovis infection.  46 
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Findings shown in this study suggest that the use of BCG vaccine,  can reduce the 47 
number and severity of lesions , induce a different phenotypic response and increase 48 
the local expression of key cytokines related to protection. 49 
Keywords 50 
Bovine tuberculosis, BCG, immunohistochemistry, cytokine, immune response. 51 
 52 
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 55 
Introduction 56 
Bovine tuberculosis (bTB), caused by infection with Mycobacterium bovis, is a disease 57 
of international importance, with an estimated 50 million cattle infected worldwide, at 58 
an annual cost of US$3 billion (Buddle et al., 2011; Waters et al., 2012). Despite the 59 
application of the test and slaughter policy, the incidence of bTB in GB has increased 60 
steadily since the 1980s and this is thought to be partly due to the existence of wildlife 61 
reservoirs (Vordermeier et al., 2006; Donnelly and Woodroffe 2015). It is thought that, 62 
in the presence of a wildlife reservoir, the test and slaughter policy will not be 63 
sufficient to stem the increase in the incidence of bTB and cattle vaccination has been 64 
proposed as a supplementary measure to reduce the duration of time that herds are 65 
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under restrictions and the number of animals removed during testing (EFSA, 2013). 66 
Furthermore, a vaccination strategy would also benefit developing countries, where a 67 
‘test and slaughter’ approach is not feasible to be implemented (Vordermeier et al., 68 
2002). 69 
However, vaccination is not currently used as part of the European bovine TB control 70 
program. The most important fact against the use of cattle vaccination is the 71 
interference of BCG with the specificity of the tuberculin skin test (Whelan et al., 72 
2011), which is the cornerstone of current surveillance and eradication strategies 73 
(Conlan et al., 2012). However, the development of diagnostic tests that can 74 
Differentiate Infected from Vaccinated Animals (DIVA) (Vordermeier et al., 2011; Jones 75 
et al., 2012) could open up the use of BCG as an important tool to complement current 76 
control programs. 77 
Reports of the use of BCG vaccination in experimentally infected cattle show that the 78 
vaccine is effective in reducing the number and severity of lesions and also the 79 
bacterial count (Johnson et al., 2006). Absolute protection is not conferred; the 80 
infecting M. bovis can often be detected in the lymph nodes draining the site of entry, 81 
however, secondary spread is slowed, or even prevented (Buddle et al., 2006; Ly et al., 82 
2007). Recent field trials and experiments under natural transmission conditions have 83 
also reported its effectiveness, although with variable levels of protection (Suazo et al., 84 
2003; Ameni et al., 2010; Lopez-Valencia et al., 2010). 85 
The evaluation of bTB lesions using a combination of gross pathology, light microscopy 86 
and immunohistochemical markers is useful to discriminate granuloma stages as 87 
Page 4 of 45Transboundary and Emerging Diseases
5 
 
indicators for the progress of infection and determine important aspects like vaccine 88 
efficacy and disease severity (Johnson et al., 2006). The main objective of this study 89 
was to characterise the immune response (differential granuloma stages and cytokine 90 
expression) within lymph node granulomas from BCG vaccinated and experimentally 91 
infected cattle with M. bovis. 92 
 93 
 94 
Materials and Methods 95 
Ethical statement 96 
This study has been carried out in accordance with the UK Animal (Scientiﬁc 97 
Procedures) Act 1986, under appropriate personal and project licences. The protocol 98 
used was approved by the APHA Ethics Review Process Committee. 99 
Experimental Infection and post-mortem examination 100 
Ten male Holstein-Friesian calves aged between 5 and 7 months were vaccinated 101 
subcutaneously with 1x106 cfu of Danish BCG (group BCG). A further ten animals were 102 
used as the non-vaccinated group. Twelve weeks later all 20 animals were challenged 103 
with 2000 cfu of M. bovis AF 2122/97 via endotracheal instillation. All cattle were 104 
obtained from herds of high health status originating from bTB-free areas and after 105 
infection with M. bovis were housed in BSL3 accommodation. Animals were 106 
euthanised using a captive bolt gun 13 weeks following infection and post-mortem 107 
examination was performed immediately by a veterinary pathologist. Lungs were 108 
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examined for lesions externally and internally by slicing at 0.5-1 cm intervals. Lymph 109 
nodes of the head and neck region: lateral and medial retropharyngeal, submandibular 110 
and parotid lymph nodes; and the bronchial and mediastinal lymphocentres : cranial 111 
tracheobronchial, left and right bronchial (tracheobronchial lymph nodes within the 112 
bifurcation), cranial and caudal and mediastinal lymph nodes were incised to inspect 113 
for lesions. Scores were assigned based on a previously scoring scheme reported in 114 
Vordermeier et al., 2002. Briefly, lung lobes (left apical, left cardiac, left diaphragmatic, 115 
right apical, right cardiac, right diaphragmatic, and right accessory lobes) were 116 
examined individually, and the following scoring system was applied: 0= no visible 117 
lesions; 1= no gross lesions but lesions apparent on slicing; 2= <5 gross lesions of <10 118 
mm in diameter; 3= >6 gross lesions of <10 mm in diameter or a single distinct gross 119 
lesion of >10 mm in diameter; 4= >1 distinct gross lesion of >10 mm in diameter; 5= 120 
gross coalescing lesions. The scores of the individual lobes were added up to calculate 121 
the lung score. For lymph nodes, the severity of the observed gross pathology in 122 
individual lymph nodes was scored applying the following scoring system: 0= no 123 
necrosis or visible lesions; 1= small focus (1 to 2 mm in diameter); 2= several small foci 124 
or necrotic area of at least 5 by 5 mm; 3= extensive necrosis. Individual lymph node 125 
scores were added up to calculate the lymph node score. Both lung and lymph nodes 126 
pathology scores were added to determine the total pathology score per animal. 127 
Additionally, samples of lymph nodes were taken for bacterial culture. Sections of the 128 
cranial and caudal mediastinal, left bronchial (tracheobronchial lymph node in the 129 
tracheal bifurcation), cranial tracheobronchial and left parotid lymph nodes were fixed 130 
in buffered formalin for further processing, as described below. The left parotid lymph 131 
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node served as a control tissue as no lesions would be expected here because of the 132 
infection route, based on previous studies by this group (Aranday-Cortes et al., 2013).  133 
Histopathology 134 
Sections of lymph nodes were stained with haematoxylin and eosin (H&E) to be 135 
examined under light microscope. Granuloma were classified in four stages (Wangoo 136 
et al., 2005). Briefly, Stage I (Initial), formed by irregular unencapsulated clusters of 137 
epithelioid macrophages, with interspersed lymphocytes and small numbers of 138 
neutrophils. Stage II (Solid), composed primarily of epithelioid macrophages and partly 139 
or completely enclosed by a thin capsule. Minimal necrotic areas were sometimes 140 
present. Stage III (Minimal necrosis), at this stage the granulomas were fully 141 
encapsulated, with central necrotic areas, which were mainly caseous and sometimes 142 
slightly mineralized. Epithelioid macrophages admixed with multinucleated giant cells 143 
(MNGCs) surrounded the necrotic areas. A peripheral zone of macrophages mixed with 144 
clusters of lymphocytes and scattered neutrophils extended to the ﬁbrous capsule. 145 
Stage IV (Necrosis and mineralization) were characterize by large, irregular, 146 
multicentric and thickly encapsulated granulomas. Prominent caseous necrosis with 147 
extensive islands of mineralization occupying the greater part of the lesion. Epithelioid 148 
macrophages together with MNGCs surrounded the necrosis, with particularly dense 149 
clusters of lymphocytes near the peripheral ﬁbrotic capsule. 150 
In addition, the number of MNGCs in each lesion were scored between 0 (no MNGCs) 151 
and 2 (many MNGCs). Ziehl-Neelsen stain (ZN) was used to determine the 152 
microscopically visible number of acid fast bacilli (AFBs) present in each granuloma.      153 
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Immunohistochemistry 154 
The IHC procedures are summarised in Table 1. Formalin fixed samples lymph nodes 155 
were cut in 4 µm sections, dewaxed and rehydrated at room temperature, and placed 156 
in a fresh solution of 3% hydrogen peroxide in methanol for 15 minutes to block 157 
endogenous peroxidise activity. Samples were then washed in tap water. These stages 158 
were carried out using a Shandon Varistain 24-4® (Shandon Scientific, Runcorn, UK). 159 
Epitope demasking was performed with different methods, according to the different 160 
primary antibodies used, as detailed in Table 1. Samples were either subjected to heat 161 
digestion, using a Thermotissuewave microwave (Shandon Scientific), or enzyme 162 
digestion, using a solution of 0.5% trypsin/0.5% chemotrypsin (Sigma, Poole, UK) 163 
adjusted to pH 7.8 with 0.1M sodium hydroxide. Running tap water was then used to 164 
wash the tissue sections and the slides were then mounted onto Shandon 165 
coverplates™ and loaded into Sequenza® trays (Shandon Scientific). The samples were 166 
washed with either tris-buffered saline (TBS) (0.85% NaCl, 0.0605% tris, adjusted to pH 167 
6.7 using 1M HCl) or TBS with 0.05% tween-20 (TBST) (Sigma), as detailed in Table 1. 168 
Goat normal serum (190 µl) was then added to the slide at a 1:66 dilution in TBS or 169 
TBST (Table 1) as blocking agent. After twenty minutes, 190 µL of the primary antibody 170 
was added. Appropriate controls were included in each IHC run. These included 171 
sequential sections with an isotype control for each primary antibody, and the 172 
omission of the primary antibody. The incubation time varied for each primary 173 
antibody used (Table 1). After two washes with TBS or TBST buffer, 190 µL of 174 
biotinylated link antibody and link block (normal goat serum) were added, followed by 175 
two further buffer washes, 30 minutes later. Primary and secondary antibody binding 176 
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was amplified using avidin–biotin–peroxidase conjugate (ABC elite; Vector 177 
Laboratories) and visualized using 3,3′-diaminobenzidine tetrahydrochloride (DAB). 178 
Unbound conjugate was removed prior to DAB application with two buffer washes. 179 
Slides were then washed in purified water, removed from the coverplates and placed 180 
in a rack. Samples were rinsed with tap water for five minutes, before being placed in 181 
Mayers Haematoxalin counterstain, followed by a further wash in tap water. Finally, 182 
sections were dehydrated, cleared and mounted for analysis. 183 
Image analysis 184 
Immunolabelled sections were analysed using light microscopy and digital image 185 
analysis (Nikon NIS Br, Nikon, Japan). All granulomas were examined with the x40 186 
objective to give a final magnification of x400, to ascertain the percentage of 187 
immunostained cells in the lesion. The whole area of the granuloma was selected as 188 
Region of Interest (ROI) and the area with immunohistochemical positive reaction 189 
within the ROI was calculated by the software after setting the thresholds. The results 190 
as expressed as the percentage of positively immunolabeled area within the total area 191 
of the granuloma.  The total number of analysed granulomas was up to 219 in the BCG 192 
group and up to 687 for the non-vaccinated group. Necrotic or mineralised areas were 193 
not included in the analysis, as described previously (Aranday-Cortes et al., 2013).  194 
Statistics 195 
χ-square analysis was applied to analyse the trend in granuloma classification 196 
(histopathology) comparison of BCG and NC group. 197 
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The results of immunohistochemical analysis are expressed as mean ± standard 198 
deviation (S.D). The mean results between groups for each granuloma stage were 199 
analysed by comparing means assuming unequal variance using the t-test with Welch 200 
approximation. Differences were considered significant at P< 0.05.  201 
All the analyses were conducted using Graph Pad Prism 4.0 (San Diego, CA, U.S.A.) and 202 
STATA10 (College Station, TX: StataCorp LP). 203 
Results 204 
Gross pathology 205 
Gross lesions were present in the lymph nodes and the lungs of 9/10 and 8/10 non-206 
vaccinated animals respectively and in the lymph nodes and the lungs of 3/10 and 4/10 207 
BCG vaccinated animals respectively (Fig. 1). Lesions were either solitary or coalescing 208 
areas of caseous necrosis. Both, BCG vaccinated and non vaccinated animals, had 209 
lesions of an identical appearance, although granulomas in vaccinated animals were 210 
generally smaller and isolated. Fig. 1 demonstrates that BCG vaccinated cattle had a 211 
lower average gross pathology score for both the lung and lymph nodes compared 212 
with non-vaccinated animals. One BCG vaccinated animal displayed lesions similar in 213 
severity to the majority of non-vaccinated cattle. Interestingly, one non-vaccinated 214 
animal had no visible lesions. 215 
Histopathology 216 
As shown in Fig. 2, there are statistically significantly fewer granulomas present in BCG 217 
vaccinated animals compared to non-vaccinated lymph nodes. Using a system 218 
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previously developed (Wangoo et al., 2005) to grade the stage of development of the 219 
granuloma it was shown that for BCG vaccinated animals, the majority of granulomas 220 
were stage I. These appeared as small, irregular clusters of predominantly epithelioid 221 
macrophages, with occasional MNGCs, lymphocytes and neutrophils. In contrast, non-222 
vaccinated animals displayed mostly stage IV granulomas, which are large and 223 
multicentric, with prominent necrosis and mineralisation and are surrounded by a 224 
thick fibrous capsule. Additionally, it was seen that stage IV granulomas were often 225 
surrounded by small stage I and II ‘satellite granulomas’. These were numerous in non-226 
vaccinated animals but were uncommon in BCG vaccinated cattle, where the majority 227 
of granulomas were isolated. The granulomas of both vaccinated and non-vaccinated 228 
cattle appeared similar microscopically, although MNGCs appeared to be increased in 229 
non-vaccinated animals. 230 
Four animals exhibited no microscopic lesions: three from BCG group and 1 from the 231 
NC group.  In contrast, one BCG vaccinated animal appeared unprotected and showed 232 
many granulomas of all stages, histologically appearing similar to many of the non-233 
vaccinated cattle. This animal contributed the majority of stage III and IV granulomas 234 
present in BCG vaccinated cattle. 235 
Examination of ZN stained sections revealed that statistically significantly fewer AFBs 236 
were present within each stage of granuloma for BCG vaccinated cattle in comparison 237 
to non-vaccinated, as shown in Fig. 3. AFBs were also more numerous in stage III and 238 
IV granulomas than stages I and II and were most commonly present within areas of 239 
necrosis, although were also located intracellularly within epithelioid macrophages and 240 
MNGCs (Fig. 3).  241 
Page 11 of 45 Transboundary and Emerging Diseases
12 
 
Immunohistochemistry 242 
Macrophages (CD68) and iNOS+ cells  243 
Immunohistochemistry for CD68 indicates the location of macrophages (including 244 
epithelioid macrophages and MNGCs). Within lymph node sections, BCG vaccinated 245 
animals showed a statistically significant reduction in the mean number of CD68+ cells 246 
for all stages of granuloma when compared to non-vaccinated animals (Fig. 4).  247 
Distribution of macrophages within lesions was similar between the BCG vaccinated 248 
and non-vaccinated groups. Macrophages were dispersed throughout stage I and II 249 
granulomas, however, were predominantly situated around the necrotic centre of 250 
stage III and IV lesions. BCG vaccinated cattle displayed fewer MNGCs than non-251 
vaccinated animals upon IHC (Fig. 4). 252 
Immunohistochemical staining for iNOS showed a higher mean percentage staining in 253 
the granulomas of BCG vaccinated animals compared to non-vaccinated cattle for all 254 
granuloma stages, being statistically significant in stages I and IV. 255 
Positive staining for iNOS was present in all stages of granulomas in both groups. 256 
Stages I and II showed scattered staining throughout and stage III and IV displayed a 257 
rim of positive macrophages, epithelioid and MNGCs surrounding the necrotic centres 258 
(Fig. 5). 259 
T lymphocytes (CD3)  260 
For each stage, a statistically significant reduction in the mean number of CD3+ cells 261 
was noted in BCG vaccinated animals compared to non-vaccinated, as shown in Fig. 6. 262 
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Distribution of CD3+ cells was similar for both groups of animals; in stages I and II CD3+ 263 
cells were dispersed throughout the granuloma, but were predominantly situated 264 
peripherally around the fibrous capsule in stage III and IV granulomas (Fig. 6). 265 
γδ T cells (WC1) 266 
Immunohistochemistry for WC1 shows the location of a subset of bovine γδ T cells, 267 
which for all granulomas examined formed a small proportion of the total cells. As 268 
shown in Fig. 7, there was a statistically significant reduction in the mean number of γδ 269 
T cells for BCG vaccinated cattle in comparison to non-vaccinated for each stage. For 270 
both groups independently, the percentage of WC1+ cells was similar when comparing 271 
each stage of granuloma development. WC1+ cells were scattered throughout stage I 272 
and II granulomas, but were present peripherally around the edge of the fibrous 273 
capsule in stages III and IV (Fig. 7). 274 
B lymphocytes (CD79a) 275 
Immunohistochemical staining for CD79a showed the location of B lymphocytes within 276 
the lesions. For granuloma stages II, III and IV, BCG vaccinated animals had a 277 
statistically significantly higher mean number of positively stained cells compared to 278 
non-vaccinated animals. Stage I granulomas of both groups had similar mean 279 
percentage of CD79a positive cells. It was also noted that BCG vaccinated animals 280 
showed an increase in the mean percentage of B cells through stages I to III, whereas 281 
non-vaccinated animals show a decrease in the mean percentage of positively stained 282 
cells between the same stages (Fig. 8).  283 
Distribution of B lymphocytes in both BCG vaccinated and non-vaccinated animals was 284 
identical for both groups of animals; stage I and II granulomas showed scattered 285 
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positive staining throughout the lesion, whereas for stage III and IV granulomas 286 
staining was peripheral. Additionally, stage III and IV granulomas were frequently 287 
surrounded by clusters of B cells situated outside the fibrous capsule (Fig. 8D).   288 
IFNγ  289 
Immunohistochemical staining for IFNγ showed a statistically significantly higher mean 290 
percentage staining in the granulomas of BCG vaccinated animals compared to non-291 
vaccinated cattle for all stages (Fig. 9). For both groups of animals, there was an 292 
increase in the percentage of cells expressing IFNγ between stages I to IV.  293 
Staining was most prominently associated with lymphocytes, with occasional 294 
macrophages also showing positivity. For both, BCG vaccinated and non-vaccinated 295 
cattle, stage III and IV granulomas showed most of cells expressing IFNγ at the 296 
periphery of the granulomas, whereas stage I and II showed staining dispersed 297 
throughout the lesion.  298 
TNFα 299 
Immunohistochemistry for TNFα shows a statistically significantly higher mean 300 
percentage of staining in BCG vaccinated animals compared to non-vaccinated for 301 
stages I, II, and III. The mean percentage of positive staining was not statistically 302 
significantly different between stage IV granulomas of both groups.  Additionally, the 303 
expression of TNFα was shown to increase between stages I to IV for BCG and non-304 
vaccinated animals (Fig. 10). TNFα expression was mostly associated with 305 
macrophages, including epithelioid and MNGCs as shown in Fig. 10. The higher 306 
numbers of MNGCs in stage IV granulomas of non-vaccinated animals could be the 307 
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cause as the expression of TNFα was very similar to that observed in stage IV 308 
granulomas of BCG vaccinated animals. Positive staining was dispersed throughout 309 
stage I and II granulomas and mostly located around the necrotic centres of stage III 310 
and IV granulomas for both BCG and non-vaccinated groups. 311 
TGFβ 312 
Immunohistochemistry for TGFβ showed that for granuloma stages I, II and III, BCG 313 
vaccinated animals displayed a lower mean percentage of positive staining; although 314 
this difference was only statistically significant when comparing stage I granulomas of 315 
the two groups (Fig. 11). Non-vaccinated animals showed a pattern of decreased TGFβ 316 
expression as the granulomas developed between stages I and IV, whereas BCG 317 
vaccinated animals showed a slight increase with lesion progression. TGFβ was 318 
expressed in all type of macrophages throughout all the layers of the granulomas (Fig. 319 
11). 320 
 321 
Discussion 322 
Eradication of bTB has proven to be difficult in some areas of UK using test and 323 
slaughter strategies, and other approaches such as cattle vaccination are being 324 
proposed. Candidate vaccines need to be tested in order to know important aspects 325 
like safety and efficacy. The evaluation of bTB lesions using a combination of gross 326 
pathology, histopathology and immunohistochemical markers is useful to determine 327 
these important aspects (Johnson et al., 2006). In this study, we have characterised the 328 
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immune response (differential cellular composition and cytokine expression in 329 
different granuloma stages) within lymph node granulomas from cattle vaccinated 330 
with BCG and non-vaccinated animals, experimentally infected with M. bovis.  331 
BCG vaccination does confer a significant degree of protection against experimental M. 332 
bovis infection in cattle (Vordermeier et al., 2002; Buddle et al., 2005). BCG vaccinated 333 
cattle exhibited a lower mean gross pathology score for both lungs and lymph nodes 334 
compared to non-vaccinated animals following M. bovis infection. This was supported 335 
by the detection of significantly fewer granulomas in the tissues of BCG vaccinated 336 
animals compared with the non-vaccinated animals by examination of H&E stained 337 
sections. Three of the ten BCG vaccinated cattle showed no detectable lesions thirteen 338 
weeks post infection. Granulomas from the majority of BCG vaccinated animals 339 
showed significantly fewer AFBs and fewer MNGCs for all stages of granulomas, 340 
suggestive of a lower bacterial load and greater ability to control infection.   341 
One BCG-vaccinated animal showed no protection from M. bovis infection, exhibiting a 342 
high gross pathology score and multiple stage III and IV granulomas. This animal also 343 
showed similar numbers of AFBs to non-vaccinated animals. One non-vaccinated 344 
animal demonstrated no granulomas upon gross or microscopic examination. 345 
BCG vaccinated cattle displayed predominantly stage I and II granulomas 13 weeks 346 
post M. bovis infection. These early stage granulomas are considered protective to the 347 
animal, in that they contain and control the replication of the bacteria, without causing 348 
the excess tissue destruction associated with stage III and IV lesions. This idea is 349 
supported by the observation that fewer AFBs were present in stage I and II 350 
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granulomas of both groups. Together this substantiates the theory that the smaller 351 
size of these lesions facilitates macrophage-lymphocyte interactions and leads to the 352 
increased production of cytokines such as IFNγ, which induce mycobactericidal 353 
pathways within macrophages (Saunders and Cooper, 2000; Cassidy, 2006; Palmer et 354 
al., 2007).   355 
IHC revealed there to be a statistically smaller percentage of macrophages (CD68+) 356 
within all stages of granuloma for BCG vaccinated cattle compared to non-vaccinated 357 
animals.. Possible reasons for this finding are that fewer MNGCs were present within 358 
granulomas of BCG vaccinated animals which, because of their large size, contribute a 359 
larger amount towards the total percentage area (Johnson et al., 2006). MNGCs cells 360 
are formed by the fusion of macrophages in response to the intracellular persistence 361 
of the pathogen, therefore, because of the lower bacterial count of the majority of 362 
BCG vaccinated M. bovis induced granulomas, fewer macrophages will have been 363 
stimulated to differentiate into MNGCs (Quinn and Schepetkin, 2009). Studies carried 364 
out in other species have found that the higher number of MNGCs in granulomas of 365 
stages III and IV is consistent with a reduced ability of the animal to contain the 366 
infection (García-Jiménez et al., 2013a, García-Jiménez et al., 2013b). In these cases, 367 
the presence of fewer MNGCs in granulomas of BCG vaccinated animals could be 368 
considered a sign of protection. 369 
. The majority of BCG vaccinated granulomas were of stages I and II and did not 370 
progress to the more advanced stages III and IV. In this sense, it is possible to speculate 371 
that despite the smaller percentage of macrophages present within these lesions, 372 
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interactions with other cells were more efficient than in non-vaccinated animals, which 373 
overall resulted in a lower bacterial count and minimal tissue damage.   374 
Statistically significantly fewer CD3+ cells were detected in the granulomas of BCG 375 
vaccinated cattle compared to non-vaccinated animals after M. bovis infection. These 376 
results are surprising since CD4+ cells (a CD3 subset) are recognised to have an 377 
important role in the production of IFNγ, which was found to be elevated in BCG 378 
vaccinated animals in this study (Pollock et al., 1996). The importance of CD4+ cells in 379 
BCG mediated protection is well documented; vaccination in mice has been shown to 380 
induce a persistent mucosal population of multifunctional CD4+ T effector memory 381 
cells, which expand following M. bovis infection (Kaveh et al., 2011). Future work could 382 
use IHC to assess the relative contributions of CD4+ and CD8+ T lymphocytes in the 383 
BCG mediated protection against M. bovis infection, to ascertain reasons for the 384 
reduction in CD3+ cells demonstrated here. 385 
The findings of this study show that 13 weeks following M. bovis infection significantly 386 
fewer WC1+ γδ T cells are present in the granulomas of BCG vaccinated cattle 387 
compared to non-vaccinated animals. This corroborates findings of a similar study 388 
which used IHC to quantify expression of WC1+ cells eighteen weeks post-infection 389 
(Johnson et al., 2006). Other studies in mice, cattle and humans have demonstrated an 390 
increase in WC1+γδ T cells within peripheral blood or lung mononuclear cells in 391 
response to BCG vaccination and following infection, these innate immune effectors 392 
quickly migrate to the tissue (Pollock et al., 1996; Dieli et al., 2003; Mazzola et al., 393 
2007; Buza et al., 2009; Kaveh et al., 2011). In particular, cells expressing the WC1.1+ 394 
isoform accumulate in the respiratory tract and pharyngeal tonsils of BCG vaccinated 395 
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calves when compared to non-vaccinated animals (Price et al., 2010). These cells 396 
secrete high levels of IFNγ which may partially explain the robust IFNγ response as 397 
detected by IHC in vaccinated cattle in this study. Differences in the findings between 398 
studies are most likely explained by the different time points at which measurements 399 
were taken. Because the immune response to M. bovis infection is highly dynamic and 400 
because γδ T cells are implicated in the innate immune response, it would is likely that 401 
the time of sampling post infection would influence the results (Wangoo et al., 2005).  402 
A statistically significant increased number of B lymphocytes was present in stage II, III 403 
and IV granulomas within the lymph node of BCG vaccinated cattle when compared to 404 
non-vaccinated animals. BCG vaccinated animals showed a general trend of increasing 405 
numbers of B cells as the lesion developed. Prominent clusters of B lymphocytes were 406 
observed surrounding later stage granulomas of both vaccinated and non-vaccinated 407 
animals, as has been observed before in cattle (Aranday-Cortes et al., 2013) and other 408 
species including human (Ulrichs et al., 2004; García-Jiménez et al., 2012). It has been 409 
suggested that these clusters resemble active follicles, as found in secondary lymphoid 410 
organs. These have been shown in humans to contain antigen presenting cells and B 411 
cells at different stages of differentiation, surrounded by CD4+ and CD8+ lymphocytes. 412 
These structures are suggested to be instrumental in directing a lasting, co-ordinated 413 
response to the mycobacterium (Ulrichs et al., 2004). 414 
IFNγ expression within lymph node granulomas of BCG vaccinated animals was 415 
significantly higher than for non-vaccinated animals. Furthermore, animals exhibiting 416 
the fewest and least advanced granulomas expressed the most IFNγ. These results are 417 
supportive of the hypothesis that IFNγ has a protective role in the response to M. bovis 418 
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infection, as reported in others studies (Welsh et al., 2005; Johnson et al., 2006; 419 
Boddu-Jasmine et al., 2008; Aguilar León et al., 2009).     420 
The results presented here potentially indicate that the CD3+ cells recruited to the 421 
lymph node following infection of BCG vaccinated animals produced higher quantities 422 
of IFNγ than CD3+ cells within the granulomas of non-vaccinated cattle. This idea is 423 
supported by the identification of multi-cytokine producing CD4+ lymphocytes induced 424 
by BCG vaccination, which produce higher amounts of IFNγ than single cytokine 425 
expressing cells (Kaveh et al., 2011; Whelan et al., 2011). Additionally, natural killer 426 
cells are innate immune effectors that produce large amounts of IFNγ when stimulated 427 
with mycobacterial antigens (Olsen et al., 2005).  Following BCG vaccination, these 428 
cells expand in both the lymph nodes and peripheral blood and so IHC using markers 429 
against CD335 (expressed on the surface of NK cells) could be used to assess the in situ 430 
contribution of these cells to BCG induced protective immunity (Siddiqui et al., 2012).     431 
Similarly to IFNγ, TNFα showed statistically increased expression in the BCG vaccinated 432 
animals compared to non-vaccinated for granuloma stages I, II and III when examined 433 
using IHC. This cytokine is a multi-functional cytokine primarily involved in the initial 434 
stages of innate immunity, which could explain the higher expression in early stages 435 
granulomas (Roach et al., 2002). TNFα has also an essential role in the induction of the 436 
chemokines and the recruitment of macrophages and T cells required to clear the 437 
intracellular bacterial infections and maintaining the microenvironment of protective 438 
granulomas (Roach et al., 2002; Boddu-Jasmine et al., 2008), as could be occurring in 439 
BCG vaccinated animals in our study. 440 
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TGFβ expression was shown to be downregulated in BCG vaccinated animals compared 441 
to non-vaccinated for granuloma stages I, II, and III, although was only statistically 442 
significant when comparing stage I granulomas. Given the role of this cytokine in 443 
suppressing IFNγ and iNOS production, this result is in agreement with our other 444 
findings (Barnes et al., 1994).  445 
An important role of TGFβ within the granuloma is the increased production of type 1 446 
collagen (Quaglino Jr et al., 1991). The slight increase of TGFβ expression between 447 
stages I to IV in BCG vaccinated animals could be associated to the formation of the 448 
fibrous capsule that surrounds more advanced granulomas. 449 
iNOS catalyses the production of nitric oxide, which inactivates infecting mycobacteria 450 
through the production of highly reactive nitrogen intermediates. The increased 451 
presence of iNOS and therefore nitric oxide, seems likely to have contributed to the 452 
much reduced bacterial count within lymph nodes of the BCG vaccinated cattle. 453 
Increased expression of iNOS is corroborated by the higher levels of IFNγ detected 454 
within the granulomas of BCG vaccinated cattle, since Th1 cytokines are important in 455 
promoting mycobactericidal pathways (Palmer et al., 2007). 456 
The increased expression of B lymphocytes within the granulomas coupled with high 457 
IFNγ production throughout the course of the experiment imply that a Th0 response 458 
(characterised by aspects of both Th1 and Th2 immune responses) has developed in 459 
the BCG vaccinated animals following M. bovis infection. This is further supported by 460 
the increased detection of TGFβ in advanced lesions of BCG vaccinated cattle.  In 461 
addition, other studies have found vaccinated animals to maintain higher levels of the 462 
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anti-inflammatory cytokines IL4 and IL10 in comparison with unvaccinated cattle 463 
(Widdison et al., 2006).  Human data also support this idea, in that BCG vaccination has 464 
been shown to stimulate both Th1 and Th2 responses, although interestingly, Th2 465 
responses are not maintained (Djuardi et al., 2012). This is believed to be an attempt 466 
by the host to reduce damage inflicted by high levels of pro-inflammatory cytokines 467 
(Blanco et al., 2009).   468 
Conclusions 469 
Findings shown in this study suggest that the use of BCG as a vaccine, even though it 470 
does not provide 100% protection from disease, reduces the number and severity of 471 
lesions and the number of ZN visible bacteria.  472 
The lower number of inflammatory cells but on the other hand the higher efficiency in 473 
the expression of beneficial cytokines with bactericidal effect by this cells, seems to be 474 
the reason of protective induced granulomas in BCG vaccinated animals in our study. 475 
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Figure captions 641 
 642 
Fig. 1. BCG confers protection against M. bovis induced pathology. Pathology scores 643 
for lungs (closed symbols) and lymph nodes (open symbols). Scores for non-vaccinated 644 
animals (diamonds) are higher than for BCG-vaccinetd cattle (circles). Bars indicate the 645 
mean for each group.   * = P<0.05 646 
Fig. 2. Protection induced by BCG correlates with the number and severity of 647 
granuloma development. Lymph node slides were analysed for the presence of 648 
granulomas, which were classified according to the system developed by Wangoo et 649 
al., 2005 as described in materials and methods. Statistically significantly fewer 650 
granulomas (P<0.05) were present in lymph nodes of BCG vaccinated animals 651 
compared to non-vaccinated. * = P<0.05 652 
Fig. 3. Acid fast bacilli (AFBs) accumulate in late stage granulomas. Acid fast bacilli 653 
(AFB) were counted as described in material and methods in the different types of 654 
granulomas . AFB were found in greater number in non-vaccinated (black bars) than in 655 
BCG-vaccinated animals (white bars).  Error bars show standard deviation  * = P<0.05. 656 
ZN staining of a MNGC from the lymph node of a BCG-vaccinated animal (A) and the 657 
necrotic centre of a stage IV granuloma from a non-vaccinated (B) animal.  658 
Fig. 4. Macrophages (CD68+). Mean percentage of positive immunolabelling within 659 
granulomas for CD68 within the lymph nodes for non-vaccinated and BCG vaccinated 660 
animals. Results are expressed as means ± SD. *P<0.05. Immunolabelling for CD68 in 661 
lymph nodes of non-vaccinated (A,B), and BCG vaccinated (C,D) animals. Numerous 662 
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CD68+ macrophages and MNGCs can be seen in stage II granulomas (A,C) and 663 
surrounding necrotic centres in stage IV granulomas (n; B,D). 664 
Fig. 5. iNOS. Mean percentage of positive immunolabelling within granulomas   for 665 
iNOS in non-vaccinated and BCG vaccinated animals for each stage of granuloma 666 
within the lymph node. Immunolabelling for iNOS in the lymph nodes of non-667 
vaccinated (A,B), and BCG vaccinated(C,D) animals. Scattered epitheliod and MNGCs 668 
were positively stained in stage I granulomas (A,C) and a rim of positively stained cells 669 
were observed surrounding the necrotic centres (n) in stage IV granulomas (B,D). 670 
Fig. 6. CD3 (T cells). Mean percentage of positive immunolabelling within granulomas 671 
for CD3 (T lymphocytes) in non-vaccinated and BCG vaccinated animals for each stage 672 
of granuloma within the lymph node. Results are expressed as means ± SD. *P<0.05. 673 
Immunolabelling for CD3 in the lymph nodes of non-vaccinated (A,B), and BCG 674 
vaccinated (C,D) animals. Numerous CD3+ T cells were positively stained scattered in 675 
stage II granulomas (A,C). Abundant scattered T cells were also observed towards the 676 
periphery of stage IV granulomas (B,D). n = necrotic centres. 677 
Fig. 7. WC1 (γδ T cells). Mean percentage of positive immunolabelling within 678 
granulomas for WC1 (γδ T cells) in non-vaccinated and BCG vaccinated animals for 679 
each stage of granuloma within the lymph node. Results are expressed as means ± SD. 680 
*P<0.05. Immunolabelling for WC1 in the lymph nodes of non-vaccinated (A,B), and 681 
BCG vaccinated (C,D) animals. Few WC1+ cells were positively stained scattered in 682 
stage I and II granulomas (A,C). The number of WC1+ cells in BCG stage I and II (C) is 683 
very low in comparison to NC animals (A). Abundant scattered WC1+ cells were also 684 
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observed towards the periphery of stage IV granulomas in non-vaccinated animals (C) 685 
compared to very few in BCG group (D). n = necrotic centres. 686 
Fig. 8. B cells (CD79+). Mean percentage of positive immunolabelling within 687 
granulomas for CD79a (B cells) within the lymph node of non-vaccinated and BCG 688 
vaccinated animals for each stage of granulomas development within the lymph node. 689 
Results are expressed as means ± SD. *P<0.05. Immunolabelling for CD79 in the lymph 690 
nodes of non-vaccinated (A,B), and BCG vaccinated (C,D) animals. Abundant B cells 691 
(CD79+) were positively stained scattered in stage II granulomas (A,C) and at the 692 
periphery of stage IV granulomas (B,D). Clusters of B cells can be observed outside 693 
stage IV granulomas (D). n = necrotic centres. 694 
Fig. 9. IFN-gamma. Mean percentage of positive immunolabelling per granuloma for  695 
IFNγ within the lymph node of non-vaccinated and BCG vaccinated animals for each 696 
stage of granuloma development. Results are expressed as means ± SD. *P<0.05. 697 
Numerous cells were positively stained for IFNγ in stage I (A,C) and through all the 698 
layers of stage IV granulomas (B,D). The expression of IFNγ was significantly higher in 699 
BCG vaccinated animals (C,D) than in non-vaccinated (A,B) n = necrotic centres. 700 
Fig. 10. TNF-α. Mean percentage of positive immunolabelling within granulomas for 701 
TNFα within the lymph node of non-vaccinated and BCG vaccinated animals for each 702 
stage of granuloma development within the lymph node. Results are expressed as 703 
means ± SD. *P<0.05. Immunolabelling for TNFα in the lymph nodes of non-vaccinated 704 
(A,B), and BCG vaccinated (C,D) animals. Numerous macrophages were positively 705 
stained for TNFα in stage II (A,C) and at the periphery of stage IV granulomas (B,D). The 706 
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expression of TNFα was significantly higher in BCG vaccinated animals (C,D) than in 707 
non-vaccinated (B,D) n = necrotic centres.  708 
Fig. 11. TGF-β. Mean percentage of positive immunolabelling within granulomas for 709 
TGFβ within the lymph node of non-vaccinated and BCG vaccinated animals for each 710 
stage of granuloma development within the lymph node. Results are expressed as 711 
means ± SD. *P<0.05. Immunolabelling for TGFβ in the lymph nodes of non-vaccinated 712 
(A,B), and BCG vaccinated (C,D) animals. Numerous macrophages were positively 713 
stained for TGFβ in stage I and II (A,C) and throughout all layers of stage IV granulomas 714 
(B,D). The expression of TNFα was significantly higher in BCG vaccinated animals (C,D) 715 
than in non-vaccinated (B,D) n = necrotic centres. 716 
 717 
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Table 1: Immune markers used for immunohistochemistry. 
 
a
Trypsin/Chemotrypsin was prepared as follows: 0.5g of trypsin,0.5g of chemotrypsin 
and 1g of CaCl2 were dissolved in 1L of distilled water and the resulting solution 
titrated to pH 7.8 using 0.1M sodium hydroxide solution. 
Primary 
antibody 
Antibody type Dilution Supplier 
Epitope demasking 
method 
Link antibody 
(dilution) 
Buffer 
CD3 
Rabbit v 
Human CD3 
(Polyclonal) 
1/500 
Dako, A0452         
(Ely, UK) 
Trypsin/Chymotrypsin
a
  
Goat v Rabbit 
(1/1000) 
TBS 
CD79a 
Mouse v 
Human CD79a 
(Monoclonal) 
1/100 
Dako M7051         
(Ely, UK) 
Microwave, 3x 6mins at 
100 °C,  in citric acid 
buffer, pH 6 
Goat v Mouse 
(1/200) 
TBS 
CD68 
Mouse v 
Human CD68 
(Monoclonal) 
1/50 
Dako M0718         
(Ely, UK) 
Trypsin/Chymotrypsin 
Goat v Mouse 
(1/200) 
TBS 
WC1 
Mouse v 
BovineWC1 
(Monoclonal) 
1/100 
Serotec MCA 8385 
(Oxford, UK) 
Trypsin/Chymotrypsin 
Goat v Mouse 
(1/200) 
TBST 
IFN-γ 
Mouse v 
Bovine IFN-ɤ 
(Monoclonal) 
1/250 
Serotec CC330 
(Oxford, UK) 
Microwave, 3x 6mins at 
100 °C,  in citric acid 
buffer, pH 6 
Goat v Mouse 
(1/200) 
TBS 
TNF-α 
Mouse v 
Bovine TNFα 
(Monoclonal) 
1/400 
Serotec MCA Ab/15-3 
(Oxford, UK) 
Trypsin/Chymotrypsin 
Goat v Mouse 
(1/200) 
TBST 
TGF-β 
Rabbit v 
Human TGFβ1 
(Polyclonal) 
1/250 
Santa  Cruz SC-146 
(Santa-Cruz, USA) 
Microwave, 3x 6mins at 
100 °C,  in citric acid 
buffer, pH 6 
Goat v Rabbit 
(1/1000) 
TBS 
iNOS 
Rabbit v 
Mouse iNOS 
(Polyclonal) 
1/500 
Millepore 06-573 
(Billerica, USA) 
Microwave, high pH 
buffer, 2x5mins at 100°C 
Goat v Rabbit 
(1/7500) 
TBST 
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Fig. 1. BCG confers protection against M. bovis induced pathology. Pathology scores for lungs (closed 
symbols) and lymph nodes (open symbols). Scores for non-vaccinated animals (diamonds) are higher than 
for BCG-vaccinetd cattle (circles). Bars indicate the mean for each group.   * = P<0.05  
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Fig. 2. Protection induced by BCG correlates with the number and severity of granuloma development. 
Lymph node slides were analysed for the presence of granulomas, which were classified according to the 
system developed by Wangoo et al., 2005 as described in materials and methods. Statistically significantly 
fewer granulomas (P<0.05) were present in lymph nodes of BCG vaccinated animals compared to non-
vaccinated. * = P<0.05  
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Fig. 3. Acid fast bacilli (AFBs) accumulate in late stage granulomas. Acid fast bacilli (AFB) were counted as 
described in material and methods in the different types of granulomas . AFB were found in greater number 
in non-vaccinated (black bars) than in BCG-vaccinated animals (white bars).  Error bars show standard 
deviation  * = P<0.05. ZN staining of a MNGC from the lymph node of a BCG-vaccinated animal (A) and the 
necrotic centre of a stage IV granuloma from a non-vaccinated (B) animal.  
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Fig. 4.Macrophages (CD68+). Mean percentage of positive immunolabelling within granulomas  for CD68 
within the lymph nodes for non-vaccinated and BCG vaccinated animals. Results are expressed as means ± 
SD. *P<0.05. Immunolabelling for CD68 in lymph nodes of non-vaccinated (A,B), and BCG vaccinated (C,D) 
animals. Numerous CD68+ macrophages and MNGCs can be seen in stage II granulomas (A,C) and 
surrounding necrotic centres in stage IV granulomas (n; B,D).  
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Fig. 5. iNOS. Mean percentage of positive immunolabelling within granulomas   for iNOS in non-vaccinated 
and BCG vaccinated animals for each stage of granuloma within the lymph node. Immunolabelling for iNOS 
in the lymph nodes of non-vaccinated (A,B), and BCG vaccinated(C,D) animals. Scattered epitheliod and 
MNGCs were positively stained in stage I granulomas (A,C) and a rim of positively stained cells were 
observed surrounding the necrotic centres (n) in stage IV granulomas (B,D).  
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Fig. 6. CD3 (T cells). Mean percentage of positive immunolabelling within granulomas  for CD3 (T 
lymphocytes) in non-vaccinated and BCG vaccinated animals for each stage of granuloma within the lymph 
node. Results are expressed as means ± SD. *P<0.05. Immunolabelling for CD3 in the lymph nodes of non-
vaccinated (A,B), and BCG vaccinated (C,D) animals. Numerous CD3+ T cells were positively stained 
scattered in stage II granulomas (A,C). Abundant scattered T cells were also observed towards the 
periphery of stage IV granulomas (B,D). n = necrotic centres.  
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Fig 7. WC1 (γδ T cells). Mean percentage of positive immunolabelling within granulomas  for WC1 (γδ T 
cells) in non-vaccinated and BCG vaccinated animals for each stage of granuloma within the lymph node. 
Results are expressed as means ± SD. *P<0.05. Immunolabelling for WC1 in the lymph nodes of non-
vaccinated (A,B), and BCG vaccinated (C,D) animals. Few WC1+ cells were positively stained scattered in 
stage I and II granulomas (A,C). The number of WC1+ cells in BCG stage I and II (C) is very low in 
comparison to NC animals (A). Abundant scattered WC1+ cells were also observed towards the periphery of 
stage IV granulomas in non-vaccinated animals (C) compared to very few in BCG group (D). n = necrotic 
centres.  
 
101x137mm (300 x 300 DPI)  
 
 
Page 41 of 45 Transboundary and Emerging Diseases
  
 
 
Fig. 8. B cells (CD79+). Mean percentage of positive immunolabelling within granulomas  for CD79a (B cells) 
within the lymph node of non-vaccinated and BCG vaccinated animals for each stage of granulomas 
development within the lymph node. Results are expressed as means ± SD. *P<0.05. Immunolabelling for 
CD79 in the lymph nodes of non-vaccinated (A,B), and BCG vaccinated (C,D) animals. Abundant B cells 
(CD79+) were positively stained scattered in stage II granulomas (A,C) and at the periphery of stage IV 
granulomas (B,D). Clusters of B cells can be observed outside stage IV granulomas (D). n = necrotic 
centres.  
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Fig. 9. IFN-gamma. Mean percentage of positive immunolabelling per granuloma  for  IFNγ within the lymph 
node of non-vaccinated and BCG vaccinated animals for each stage of granuloma development. Results are 
expressed as means ± SD. *P<0.05. Numerous cells were positively stained for IFNγ in stage I (A,C) and 
through all the layers of stage IV granulomas (B,D). The expression of IFNγ was significantly higher in BCG 
vaccinated animals (C,D) than in non-vaccinated (A,B) n = necrotic centres.  
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Fig. 10. TNF-α. Mean percentage of positive immunolabelling within granulomas  for TNFα within the lymph 
node of non-vaccinated and BCG vaccinated animals for each stage of granuloma development within the 
lymph node. Results are expressed as means ± SD. *P<0.05. Immunolabelling for TNFα in the lymph nodes 
of non-vaccinated (A,B), and BCG vaccinated (C,D) animals. Numerous macrophages were positively stained 
for TNFα in stage II (A,C) and at the periphery of stage IV granulomas (B,D). The expression of TNFα was 
significantly higher in BCG vaccinated animals (C,D) than in non-vaccinated (B,D) n = necrotic centres.  
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Fig. 11. TGF-β. Mean percentage of positive immunolabelling within granulomas  for TGFβ within the lymph 
node of non-vaccinated and BCG vaccinated animals for each stage of granuloma development within the 
lymph node. Results are expressed as means ± SD. *P<0.05. Immunolabelling for TGFβ in the lymph nodes 
of non-vaccinated (A,B), and BCG vaccinated (C,D) animals. Numerous macrophages were positively stained 
for TGFβ in stage I and II (A,C) and throughout all layers of stage IV granulomas (B,D). The expression of 
TNFα was significantly higher in BCG vaccinated animals (C,D) than in non-vaccinated (B,D) n = necrotic 
centres.  
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